CHAO HUANG
Partner·Beijing
CHAO HUANG
Partner·Beijing
-
CHAO HUANG
Partner·Beijing
PROFILE REPRESENTATIVE MATTERS AND CASES OTHER INFORMATION Further Reading
MR. HUANG SPECIALIZES IN M&A, PRIVATE EQUITY INVESTMENTS AND ONSHORE OFFERING AND LISTING OF SECURITIES.
Education
New York University School of Law, LL.M., Hauser Global Scholar, 2020
Peking University Law School, LL.M., 2013
Peking University National School of Development, Bachelor of Economics, 2011
Peking University Law School, LL.B., 2011
Professional Qualification
Admitted to practice in the PRC
Professional Background
Mr. Huang joined Fangda in 2015. Before joining the firm, he worked at another first-tier PRC law firm in Beijing.
PROFILE
REPRESENTATIVE MATTERS AND CASES
- Advised WuXi AppTec (603259.SH/2359.HK) on its acquisition of 100% equity stake in HD Biosciences Co., Ltd., its acquisition of 100% equity stake in Jiangsu Safe Pharmaceutical Co., Ltd., and the establishment of a joint venture offering healthcare big data solutions
- Advised CICC Capital on its acquisition of the majority stake in Shell Zhejiang
- Advised China National Integrated Circuit Industry Investment Fund on its investments in a number of PRC listed or unlisted semiconductor enterprises, including SMIT (2239.HK), Navtech (300456.SZ), AMEC (688012.SH) and Centec
- Advised VeriSilicon (688521.SH) and AMEC (688012.SH) on their onshore and offshore restructuring and multiple rounds of equity financing
- Advised Avary Holding (002938.SZ) and WuXi AppTec (603259.SH/2359.HK) on their pre-IPO equity financing, and COFCO W&W on its equity financing
- Advised multiple private equity firms including Fonestone Capital and CEC Innovation Fund on various types of investments primarily focusing on the non-financial institutions’ payment services, internet content provider and semiconductor industries
- Advised VeriSilicon (688521.SH) on its IPO and A-share listing on the STAR Market of the Shanghai Stock Exchange
- Advised AMEC (688012.SH) on its IPO and A-share listing on the STAR Market of the Shanghai Stock Exchange
- Advised WuXi AppTec (603259.SH/2345.HK) on its IPO and A-share listing on the Main Board of the Shanghai Stock Exchange
- Advised Konruns Pharmaceutical (603590.SH) on its IPO and A-share listing on the Main Board of the Shanghai Stock Exchange
- Advised Sichuan Haowu Electromechanical Co., Ltd. (000787.SZ) on its issuance of shares and cash payments in its acquisition of Neijiang Pengxiang Investment Co., Ltd.
- Advised the sole sponsor and underwriter on Maxscend’s (300782.SZ) IPO and A-share listing on the Growth Enterprises Market of the Shenzhen Stock Exchange
- Advised the co-lead underwriter on CATL’s (300750.SZ) IPO and A-share listing on the Growth Enterprises Market of the Shenzhen Stock Exchange
- Advised the sponsor or the underwriter on the non-public A-share offerings of multiple companies, including Yiling Pharmaceutical (002603.SZ) and Yibai Pharmaceutical (600594.SH)
- Advised the underwriter on China Molybdenum Co., Ltd.’s (603993.SH/3993.HK) public offering of A-share convertible bonds in the amount of RMB 4.9 billion
- Advised Synbio Technology (871854) on its listing on the National Equities Exchange and Quotations
